by Team Small News | Nov 12, 2025 | Aurobindo Pharma, Pharma
Motilal Oswal has recommended a “buy” rating for Aurobindo Pharma, with a target price of Rs 1350. The brokerage firm is optimistic about the company’s future prospects, driven by its strong product pipeline, increasing presence in the US market, and... by Team Small News | Nov 7, 2025 | Aurobindo Pharma, Pharma
Aurobindo Pharma, a leading pharmaceutical company, has released its consolidated financial results for the quarter ended September 2025. The company’s net sales for the quarter stood at Rs 8,285.70 crore, representing a year-over-year (Y-o-Y) growth of 6.28%....
by Team Small News | Nov 1, 2025 | Apollo Hospital, Aurobindo Pharma, Lupin, Pharma, Sun Pharma
The Indian corporate sector has reported earnings in line with expectations for the September quarter, boosting market sentiment. Several prominent companies, including Indian Oil Corporation, Adani Green Energy, and Hindustan Petroleum Corporation Limited, have...